Recombinant lactoferrin - Ventria Bioscience

Drug Profile

Recombinant lactoferrin - Ventria Bioscience

Alternative Names: rhLactoferrin; VEN 100; VEN 101; VEN 120; VEN 130; VEN 140; VEN 150

Latest Information Update: 01 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ventria Bioscience
  • Developer Johns Hopkins University; Minneapolis Medical Research Foundation; Rocky Mountain Poison and Drug Center; University of Colorado at Denver; Ventria Bioscience
  • Class Anti-inflammatories; Antibacterials; Antidiarrhoeals; Antineoplastics; Glycoproteins; Iron binding proteins; Recombinant proteins
  • Mechanism of Action Immunomodulators; Macrophage stimulants; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Inflammation
  • Phase I Inflammatory bowel diseases
  • Discontinued Diarrhoea; Liver failure; Osteoporosis

Most Recent Events

  • 14 Aug 2017 Ventria Bioscience initiates enrolment in a phase II trial in Inflammation (In the elderly) in USA (PO) (NCT02968992)
  • 01 Dec 2016 Ventria Bioscience and Minneapolis Medical Research completes a phase II trial in Inflammation (In adults, In the elderly) (in HIV infected patients) in USA (PO) (NCT01830595)
  • 17 Nov 2016 Johns Hopkins University and Ventria Bioscience plan the phase II ELCIE trial for chronic Inflammation (In the elderly) in USA (PO, capsule) (NCT02968992)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top